Part 2 of our look at the unique business model and ambitious plans of Civica Rx.
Drug development, in general, is a challenging feat. When it comes to orphan drugs, however, those challenges are compounded. As more orphan drugs are developed, pharma companies can tap into some of the successful strategies that have worked previously.
Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.
“This was a real turnaround type of challenge, and I knew it was going to be a steep learning curve for me,” says Steven Yatomi-Clarke of Prescient Therapeutics. “In fact, at the time, I probably underestimated the amount of work it was going to take to get the company up to scratch.”
Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.
The nonprofit CivicaRX continues to gain momentum, and the company’s president and CEO, Martin Van Trieste, believes it’s a business model that is “pro-competition,” and one that others throughout the biopharma industry can adapt as well.
Xencor’s story seems riddled with more than your average share of challenges, hurdles, and outright roadblocks. But it’s the outcome of that story — a growing company now valued at roughly $1.8 billion with nine drugs in the clinic and 150 employees — that truly make’s Xencor’s journey so compelling.
A lot of Big Pharma companies were on the sidelines because they were unclear how cannabinoid therapeutics would be regulated by the FDA,” explains Alex Wasyl, CEO of Nexien BioPharma.
So, why should pharma care about digital therapeutics? This was just one of the questions posed to a panel of digital therapeutics experts during the 2018 CNS Summit.
While some might think Orchard’s whirlwind rise to be a bit of luck and good timing, the reality is it involved an extremely well-executed plan — and maybe a small dose of good fortune.
An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.
Bari Kowal, VP and head of global clinical operations at Regeneron, says sponsors and CROs must partner to make clinical trial execution more efficient and cost-effective.
An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.
Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.
Pfizer’s top scientist, Mikael Dolsten, M.D., Ph.D., talks about being hyper focused during company’s R&D turnaround amongst CEO turnover, company integrations and M&A.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Rob Wright digs into the “extreme teaming” work of Amy Edmondson, Novartis professor of leadership and management at Harvard, and Jean-Francois Harvey, assistant professor at HEC Montreal, drawing on the 2010 Chilean mining disaster as an example.
Rob Wright highlights the “integrative thinking” work of Jennifer Riel and Roger Martin, professors at the Rotman School of Management, University of Toronto, in helping leaders make great choices, drawing on LEGO’s entry into feature films as an example.
